Grade 3/4 toxicities (≥5.0%) included anemia, thrombocytopenia, dyspnea, neutropenia, fatigue, and pneumonia. Belinostat is the third drug to receive accelerated approval for the treatment of relapsed or refractory PTCL.
Introduction
Peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of disorders representing approximately 10% to 15% of all non-Hodgkin lymphomas in North America and have a poor prognosis (1, 2) . According to the International T-Cell Lymphoma Project data (1314 cases from 22 countries worldwide), the most common subtypes were PTCL not otherwise specified (PTCL-NOS, 25.9%), angioimmunoblastic T-cell lymphoma (AITL, 18.5%), natural killer (NK)/T-cell lymphoma (10.4%), adult T-cell lymphoma/leukemia (ATLL, 9.6%), and anaplastic large cell lymphoma [ALCL: anaplastic lymphoma kinase (ALK)-positive, 6.6% and ALK-negative, 5.5%)] (3). PTCL has an aggressive clinical course with inferior outcomes compared to aggressive B-cell non-Hodgkin's lymphomas, and the overall 5-year disease-free survival is less than 30% (except for, ALK-positive ALCL) (4).
Although not specifically approved as regimens, commonly used first-line therapies for PTCL include CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) and HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate and cytarabine) (5) . Relapse is common after initial treatment, and there are few effective options for salvage therapy (6). Stem cell transplantation is a potentially curative treatment option for only a subset of patients. Until recently, pralatrexate and romidepsin were the only two drugs approved for the treatment of relapsed or refractory PTCL; however, from a regulatory standpoint they are not considered as available therapy because they were approved under the accelerated approval regulations and have not been converted to regular approval (7).
Chemistry
Beleodaq is a histone deacetylase (HDAC) inhibitor with a sulfonamide-hydroxamide structure.
The chemical name is (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide. The drug is supplied as a sterile lyophilized powder containing 500 mg belinostat in a single-use vial for reconstitution. Each vial also contains 1000 mg L-Arginine, USP as an inactive ingredient. After reconstitution with 9 mL of Sterile Water for injection it is further diluted with 250 mL of sterile 0.9% Sodium Chloride injection before intravenous infusion.
Pharmacology and Toxicology
HDACs catalyze the removal of acetyl groups from the lysine residues of histones. While histones are a principal substrate for HDACs, other non-histone proteins, including transcription factors, are also targeted by these enzymes. Functional outcomes of HDAC inhibition important to their anti-cancer mechanisms include apoptosis and cell cycle arrest of some transformed cells. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells.
Repeat-dose toxicology studies of up to 24-week duration were conducted in rats and dogs. Toxicities were primarily related to the gastrointestinal system, hematopoietic system (cytopenias), lymphoid system (lymphoid tissue atrophy), genitourinary system and the site of injection. Cardiovascular toxicities included cardiomyopathy and tachycardia.
Belinostat was positive for genotoxicity in the three assays used. Animal studies to evaluate the reproductive and developmental potential of belinostat were not conducted because belinostat is genotoxic and targets rapidly dividing cells and, therefore, is expected to cause teratogenicity and/or embryo-fetal lethality.
The dose for the phase 2 PTCL trial was selected using data from two phase 1 dose-escalation trials in patients with solid tumors and advanced hematological malignancies. The 1000 mg/m 2 dose, given on days 1-5 of a 21-day cycle, was determined to be the MTD in these phase 1 trials.
It was shown that body surface area based dosing provides consistent exposure across all body sizes. Dose-dependent acetylation (a pharmacodynamic marker for HDAC enzymatic activity) was observed after the first dose and appeared to plateau at doses of 900 mg/m 2 and above.
In vitro studies showed that belinostat is primarily (80-90%) metabolized by UGT1A1 and to a lesser extent by CYP2A6, CYP2C9, and CYP3A4. The sponsor did not conduct human drugdrug interaction studies to evaluate the influence of liver enzyme inhibitors of UGT1A1, CYP2A6, CYP2C9, and CYP3A4 on the systemic exposure of belinostat. Available data indicate that UGT1A1 inhibitors will likely produce meaningful belinostat exposure increases that could lead to dose-limiting toxicities. In addition, since UGT1A1 is a known polymorphic enzyme with allelic variants that influence enzymatic activity, subjects homozygous for UGT1A1*28 may have up to 20% greater belinostat exposure than subjects with UGT1A1*1. Other UGT1A1 reduced function alleles may have a similar impact on belinostat exposure.
Belinostat was shown to inhibit CYP2C8 and 2C9 in in vitro studies. However, a pharmacokinetic study in patients with cancer showed that the C max and AUC of the CYP2C9 substrate warfarin were similar in the absence and presence of belinostat, indicating that belinostat does not alter the pharmacokinetics of CYP2C8 and CYP2C9 substrates.
Limited data suggest that 40% of the administered belinostat dose was excreted in urine, mostly in the form of metabolites. Human mass balance and hepatic impairment studies are currently ongoing to fully characterize the disposition of belinostat.
Clinical Trial
Research. Efficacy was determined by a central blinded IRC review.
Tumor assessments were made according to the International Working Group (IWG) criteria. Computerized tomography (CT) scans of the neck, chest, abdomen and pelvis, and other documentation (i.e., skin lesions using a ruler) were conducted to assess tumor status.
Assessments were performed at baseline and, using the same techniques, every 6 weeks for the first 12 months, then every 12 weeks until 2 years from the start of study treatment. Radiological assessments were discontinued at the time of tumor progression or initiation of new anti-cancer therapy. Patients were followed for survival every 3 months until 2 years from the start of belinostat treatment or until trial closure.
Belinostat 1000 mg/m 2 was administered by intravenous infusion over 30 minutes once daily on days 1-5 every 3 weeks until disease progression or unmanageable treatment-related toxicities. The infusion time could be extended to 45 minutes if patients experienced pain at the infusion site or other symptoms attributable to the infusion. Belinostat dose delays or modifications were conducted for drug toxicities.
Results
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The trial enrolled a total of 129 patients from 62 sites in 16 countries. Efficacy analyses were based upon the 120 patients who had confirmed diagnoses of PTCL by the CPRG and had received at least one dose of belinostat. Approximately 90% of the patients were from US and Europe. The median age was 64 years (range, 29 -81), approximately half of the patients were male, and most of patients were White and had Eastern Cooperative Oncology Group (ECOG) performance score of 0-1. The median number of prior systemic therapies was 2 (range, 1-8), and 37% of patients had received 3 or more prior therapies ( Table 1 ). The majority of patients had PTCL-NOS (64%), followed by AITL (18%) and ALK-negative ALCL (11%). A few patients had other PTCL subtypes. The majority of patients had Stage III (35%) or Stage IV (50%) disease.
Efficacy
The IRC-assessed ORR was 26% with a CR rate of 11% and PR rate of 15%. The median DoR as evaluated from the first date of response to disease progression or death (based on the 31 responding patients) was 8.4 months (95% CI, 4.5-29.4). Median time to response was 6 weeks (range, 4-50). As assessed by investigators, the ORR was 23% (95% CI, 15.4-31.0) and the CR and PR rates were 9% and 13%, respectively. Table 2 lists the results of the primary and key secondary endpoints.
In subgroup analyses, the ORRs were 35.6% and 16.4% for patients who were ≥ 65 and < PFS and OS results are not reported here as they are not interpretable in a single-arm trial. ORR generally is the only endpoint that can be reliably assessed in a single-arm trial because the observed effect on tumor size reduction is directly attributed to the drug and is generally not associated with the natural history of the disease (8) . In addition, single-arm trials do not allow an evaluation of time-to-event endpoints (i.e., OS and PFS) because they lack information on when the event would have occurred in a group that did not receive the product being tested. In addition, because of variability in the natural history of many forms of cancer, a randomized study is necessary to evaluate time-to-event endpoints (9) .
Safety
The safety analysis population was comprised of 129 patients. The median duration of belinostat treatment was 7 weeks (range 3-135), the median number of cycles was 2 (range 1-33), and the median number of belinostat doses received by patients was 10 (range 1-165). Eighty-eight percent of patients received the drug without dose reductions. Nineteen percent of patients experienced an adverse reaction resulting in belinostat discontinuation. Nine patients (7.0%) died during the trial or within 30 days of the last dose of belinostat unrelated to disease progression: multi-organ failure (2 patients), cardiac failure (2), hepatic failure (1), lung infection (1), gastrointestinal hemorrhage (1), euthanasia (1) and shock (1). However, only the death due to hepatic failure was assessed as related to the study treatment.
The most frequently reported adverse reactions (>25%) were nausea, fatigue, pyrexia, anemia and vomiting (Table 3) . Grade 3/4 toxicities (≥5.0%) included anemia (10.9%), thrombocytopenia (7.0%), dyspnea (6.2%), neutropenia (6.2%), fatigue (5.4%), and pneumonia 
accelerated approval. The FDA is willing to approve more than one product under accelerated approval in a specific disease setting, because should one of the products fail to demonstrate clinical benefit in the confirmatory trial, there would be treatments available for patients with relapsed/refractory PTCL. Therefore, accelerated approval was granted for belinostat.
The safety profile of belinostat was considered to be acceptable for a serious and lifethreatening disease such as PTCL where there are limited treatment options. In general, the major toxicities of belinostat appeared to be similar to those observed with romidepsin, another HDAC inhibitor. Again, although cross-study comparisons must be interpreted with caution, grade 3/4 hematologic toxicities occurred less often in the belinostat trial than in the romidepsin and pralatrexate trials. It is important to note that CLN-19 was a single-arm trial and therefore the safety profile of belinostat could not be fully evaluated. As a postmarketing requirement (PMR), the safety profile and efficacy of belinostat will be further evaluated in a randomized trial intended to confirm clinical benefit.
At this time, none of the three drugs approved for PTCL under the accelerated approval regulation have been converted to regular approval. As both pralatrexate and belinostat are marketed by the same company, it was determined that a single trial would be the optimal path forward to expedite the fulfillment of PMRs for both drugs. Thus, the FDA replaced the existing PMRs for pralatrexate with the following clinical trial that could also fulfill the PMR for to a shared control arm and not the relative activity of each of these drug combinations to one another. A separate phase 1 dose escalation trial with each drug combination will be conducted before the phase 3 trial to establish the optimal and safe dose of each drug to be used in combination with the CHOP regimen. 
